Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
about
Interpretation of cytogenetic results in multiple myeloma for clinical practiceMolecular pathogenesis of multiple myeloma: basic and clinical updatesFAM46 proteins are novel eukaryotic non-canonical poly(A) polymerasesAdvances in understanding prognosis in myeloma.Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.MicroRNA: important player in the pathobiology of multiple myelomaImplications of heterogeneity in multiple myeloma.Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesTranslocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization.Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceMolecular pathogenesis of multiple myeloma and its premalignant precursor.The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple MyelomaHeterogeneity of genomic evolution and mutational profiles in multiple myeloma.The genetic architecture of multiple myeloma.Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.Understanding the molecular biology of myeloma and its therapeutic implications.IMWG consensus on risk stratification in multiple myeloma.Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.Utilizing next-generation sequencing in the management of multiple myeloma.Gene integrated set profile analysis: a context-based approach for inferring biological endpointsFAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.Mutational landscape reflects the biological continuum of plasma cell dyscrasias.Genomic Aberrations in Multiple Myeloma.Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma.Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple MyelomaAntimetastatic effects of norcantharidin on hepatocellular carcinoma cells by up-regulating FAM46C expression.
P2860
Q26777803-67F0C407-E96D-449B-BD90-6AE5804D1210Q27026205-5B8CFB46-0BE5-4221-AC2B-FF2237AC1FD9Q28603241-D1DEB852-8A97-4153-8910-78B03C7CC572Q30244061-756B0B3D-D24D-49F0-BC36-3D5E2E54F81DQ33768000-9C438A0D-145C-4011-8B29-C643511C8450Q33786861-5C425D7C-C5D0-4C20-B1FE-854D33C98A3EQ33914824-7C03DE36-D704-4467-A109-B88BE984BCF7Q34020965-0E230788-FE64-471F-A72C-06C915A18AEEQ34272540-D848AF52-D1CA-421C-87C3-5CAF7E989FC7Q34410261-2B3BF44A-72C8-4E1D-A80D-9DB0203998C1Q34669975-C437C33A-AB8C-4E5B-BD24-F41A60A6FCD4Q34682133-BB84009C-E61D-4EB2-A90D-7EB77BD99061Q35220653-85D28F58-68FF-4217-8A42-478B541B6CADQ36290238-8350B51A-B178-4D13-BDF3-AC645932BB5BQ36962747-CC3545FA-44DE-47A3-8F0C-70B900B1F6FDQ37037265-F5C0622E-2348-4FED-B0EB-1A522C993207Q37231523-956E791B-C5CA-481A-B891-F5BED0993C5EQ37528285-7A82040F-E26A-4951-A900-F885D5AE7AF0Q37718836-A0768348-9538-4FD6-84B0-F72B8ABA7A84Q37744796-83E0EA5F-EBDF-4C70-8721-B5C23ED292F6Q38065305-38626DAA-23B0-498D-A4BD-7B66E7A75037Q38131380-79764AE0-07C2-42BF-9ED6-6FF1088E2AF1Q38348173-1DD8F7B6-0628-451C-947D-1EDEECD8E3E9Q38681814-32B24832-FC5B-4BB9-9DE9-BC3E64409E8AQ38798005-F351668D-5762-4515-84AD-FC1115B78676Q38877274-5E5B7F2C-DDAF-4B1B-ABC2-5BD8DE0B505DQ38915277-8D934396-28FD-45F5-A38A-0CA839DAC5AEQ38943973-8BC446F7-B748-49E1-895A-EE1F4808F0DEQ38970573-317DA2AF-2488-4601-AC73-81D8858F2B1BQ39021977-123064F4-1FB5-4E7B-BA32-CB2E4EB92790Q39137868-A7DB5227-A0C1-400F-A2E8-B68610540D57Q39518931-D41B884D-4CFF-4CE7-B5D3-30AE4656E424Q39788992-A97CDC8D-918E-42B9-80FE-AC2D405BAF85Q40382947-74536BAF-AACB-4369-B2F4-8DB551B949AAQ40492260-4748C806-6BFF-41C0-8971-CA46D9401124Q41701047-1FB50645-2C6C-4A72-82C5-795A711A5356Q41760786-9045612C-5C0B-4E19-80EA-4BBAAB7B3FA1Q41766580-C8018385-8406-45E6-8BC6-D568C11BBB3FQ42055422-BE031231-5BDA-4AD2-9A27-4D2A95146851Q42329076-033C54FA-ACA6-4BCD-B5C4-1AD8B950259E
P2860
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@ast
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@en
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@nl
type
label
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@ast
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@en
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@nl
prefLabel
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@ast
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@en
Mapping of chromosome 1p delet ...... ociated with adverse survival.
@nl
P2093
P2860
P50
P1476
Mapping of chromosome 1p delet ...... sociated with adverse survival
@en
P2093
Faith E Davies
Fiona M Ross
Graham H Jackson
J Anthony Child
Laura Chiecchio
NCRI Haematology Oncology Studies Group
Walter M Gregory
William J Tapper
Zoe J Konn
P2860
P304
P356
10.1158/1078-0432.CCR-11-1791
P407
P577
2011-10-12T00:00:00Z